INTRODUCTION

Plasma therapy emerged as a valuable approach for pathogen immunotherapy for acute infectious diseases, since the therapeutic effects of diphtheria antitoxin plasma in 1891 were reported by Behring and Kitasato. In severe and critically ill patients of an emerging infection, the disease progression was rapid. During the starting phase, the target organs were damaged directly by the pathogens leading to severe immunopathological damage. These pathogens can be effectively and directly neutralized by passive immune antibodies reducing damage to the target organs and further blocking subsequent immunopathological damages [1].

Prevention and treatment of human infectious diseases by passive immunization started in the late 19th century. The possible use of whole convalescent blood and convalescent plasma for treating contagious diseases come into the spotlight during the Ebola virus outbreak in West Africa as it was the only therapeutic approach available in some cases due to the unavailability of drugs, vaccines, or other specific treatments [2,3]. Initially, the COVID-19 outbreak resulted in a high mortality rate due to a lack of effective and particular treatments. The non-availability of effective therapy for the COVID-19 pandemic has resulted in more than 1,160,000 deaths till October 27, 2020 worldwide. As mortality rate is an important parameter that concerns the public, clinical treatments that can decrease the fatality rate of critical cases virtually are urgently required to avoid public panic.

Researchers and scientists are continually searching for various treatment alternatives for developing vaccines and medicines to fight this life-threatening disease. Convalescent blood products can be a better alternative in the prophylaxis/treatment of some infectious diseases both as the single therapy when a specific treatment is not available and also in association with other drugs/preventive measures [4-7]. There are many potential convalescent plasma donors and critically ill patients requiring convalescent plasma treatment in hospital. Nevertheless, there are various arguments for considering the implementation of a large-scale convalescent plasma transfusion program [1].

CONVALESCENT PLASMA

Convalescent plasma refers to plasma obtained from a patient who has recovered from an infection. During the disease, the patient's immune system escalates an attack on the invading virus, and the body develops antibodies [8,9]. These antibodies are suspended in the circulating blood and can be separated from one of the components of blood – the plasma [10]. Notably, convalescent plasma was found to be effective against the Spanish flu pandemic in 1918. At that time, convalescent plasma was used by the U.S. military to treat flu patients. More recently, WHO approved it as an empirical treatment against Ebola virus infections in 2015, and it was deployed with success against the SARS (severe acute respiratory syndrome) in 2002–2003 and middle east respiratory syndrome in 2012 as well [10-13].

In the context of COVID-19, FDA guidance has been issued that provides recommendations to health care personnel and investigators for the administration of investigational convalescent plasma obtained from individuals recovered from COVID-19 during the public health emergency. The guidance illustrates recommendations on the following aspects: (i) Pathways for the use of investigational COVID-19 convalescent plasma, (ii) eligibility of patient (iii) collection of COVID-19 convalescent plasma, including eligibility and qualifications of donor, (iv) labeling of convalescent plasma, and (v) efficient record keeping [14].

Approaches for utilization of COVID-19 convalescent plasma

Since COVID-19 convalescent plasma is awaiting approval by the FDA, it is being used as an investigational drug. In these circumstances, health care personnel should follow one of the pathways detailed in Table 1. USFDA itself does not collect/provide COVID-19 convalescent plasma, but the product can be procured from an FDA registered blood establishment maintained by health care providers or acute care facilities [14].
Procedure for obtaining a single patient emergency IND
The request can be made by the provider at different time periods during a day according to Eastern Standard Time (EST) as follows:

(i) For the requests between 8 am EST and 8 pm EST (Mon-Sun), the requesting physician may submit Form 3926 downloaded from https://www.fda.gov/media/98616/ by email to CBER.eIND_Covid-19@FDA.HHS.gov. FDA will respond within four h for the eIND requests submitted through email during this time frame. The completed form should include:

- A short clinical background of the patient including the reason for the request for investigational COVID-19 convalescent plasma treatment with the purpose to meet the requirements mentioned in 21 CFR 312.305 and 312.310.
- Name of the blood establishment collecting COVID-19 convalescent plasma.
- The provider should fill the form electronically, if possible.
- Providers should ensure maximum completeness of the form, and the FDA will contact the provider if the need arises.
- The FDA will review the request and, upon validation, send the requesting physician a confirmation email (including the emergency IND number).

(ii) For requests between 8 am EST and 8 pm EST when the provider cannot complete and submit the form FDA 3926 due to mitigating circumstances, the provider can contact the FDA’s Office of Emergency Operations to seek verbal authorization.

(iii) In case of a medical emergency, for the requests made between 8 pm and 8 am, the convalescent plasma provider should necessarily obtain verbal authorization of the Food Drug and Administration office of Emergency Operations. If verbal consent is disposed of, the requesting physician must agree to submit an expanded access application (Form FDA 3926) within the timeframe of 15 working days in accordance with section (21 CFR 312.310(d)(2)).

Patient eligibility
For expediting the requests for eINDs to use COVID-19 convalescent plasma for treating severe patients, the patient eligibility criteria should be in accordance with the National Expanded Access Treatment Protocol. These include (14,16):

- Age of ≥18 years.
- Laboratory confirmed COVID-19 report.
- Severe or immediately life-threatening COVID-19, as mentioned in Table 2.
- Informed consent is given by the patient or healthcare proxy.
- The blood type of patient. Convalescent plasma must be ABO compatible with the recipient’s blood type.

Collection of COVID-19 convalescent plasma
It is mandatory for the acute care facilities and health care providers intending to use COVID-19 convalescent plasma, in the eIND submission, to mention that the COVID-19 convalescent plasma will be procured from an FDA-registered blood establishment that abides by the donor eligibility criteria and donor qualifications in the collection of plasma from donors as detailed below:

Donor eligibility
a. Plasma can be collected from the individuals meeting all donor eligibility requirements according to 21 CFR 630.10, 21 CFR 630.15. The additional donor eligibility requirements for plasma collection by plasmapheresis can be found in 21 CFR 630.15 (b). Donated plasma should be tested for all the applicable transfusion-transmitted infections (21 CFR 61.40), and the donation must be satisfactory (21 CFR 630.30) [8].

b. The following qualifications should be met by the donor [14,20-22]:

- Confirmation of COVID-19 by a laboratory test either by a diagnostic test during illness OR by the presence of SARS-CoV-2

| Pathways | Procedure/Protocol | Section |
|----------|-------------------|---------|
| Clinical trials | To consider the application of convalescent plasma for a clinical trial, a request should be submitted by the investigator to FDA for the investigational purposes under the conventional IND regulatory pathway. Center for Biologics Evaluation and Research (CBER’s) Office of Blood Research and Review is responsible for dealing with investigators and reviewing these requests promptly. INDs can be submitted through email to CBERDCC_eMailSub@fda.hhs.gov during the current COVID-19 pandemic situation. | 21 CFR Part 312 |
| Expanded access | For those patients with severe or immediately life-threatening COVID-19 disease who are ineligible or who are unable to take part in randomized clinical trials, an IND application for expanded access can be an option for using COVID-19 convalescent plasma. For opening an expanded access protocol so that COVID-19 convalescent plasma can be made available across the country, the FDA has worked with multiple federal partners and academia. This investigational product can be accessed by the involvement of acute care facilities in an investigational expanded access protocol under an IND that already exists. [15]. | 21 CFR 312.305 |
| Single patient emergency IND | Even though involvement in clinical trials or an expanded access program is pathways for patients to procure convalescent plasma, for several reasons, it may not be promptly available to all patients in potential need. Hence, during this public health emergency due to the COVID-19 pandemic, when clinical trials are undergoing, and a national expanded access protocol is available, USFDA is also encouraging availability of COVID-19 convalescent plasma to patients with severe or immediately life-threatening COVID-19 infections through submission of the request for a single patient emergency IND (eIND) for the individual patient from the patient’s physician. This pathway permits the utilization of an investigational drug for treating a particular patient under the supervision of a licensed physician upon FDA approval, if all the applicable eligibility criteria are fulfilled. However, under these conditions, an authorized physician should send a request for the eIND (see 21 CFR 312.310[b]) for administering COVID-19 convalescent plasma to an individual patient. | 21 CFR 312.310 |

| Conditions | Severe disease | Life-threatening disease |
|------------|---------------|-------------------------|
| Shortness of breath (dyspnea) | Respiratory failure | |
| Respiratory frequency ≥30 min | Septic shock | |
| The ratio of partial pressure of arterial oxygen to the inspired oxygen should be <300 | Multiple organ dysfunction or failure | |
| Blood oxygen saturation ≤ 93% | | |
| More than 50% of lung infiltrates within 24-48 h | | |

Table 2: Conditions defining severe and life-threatening COVID-19 [14-19]

Table 1: Pathways available for administering or studying the use of COVID-19 convalescent plasma [14]

Porwal et al. Asian J Pharm Clin Res, Vol 14, Issue 2, 2021, 6-14
antibodies after recovery (if initially diagnostic testing was not performed when COVID-19 was suspected).  
- The donor should be completely symptom-free at least 14 days before plasma donation. Notably, a negative result for COVID-19 by a diagnostic test is insufficient to meet the donor eligibility [23].  
- The donor can be either male or female. For females, the donor should not be pregnant or has negative report for human leukocyte antigen (HLA) antibodies.  
- The body weight for male donors should be >50 kg and >45 kg for females.  
- At least 1 week since last glucocorticoid usage.  
- More than 2 weeks since the last blood donation.  
- Establish SARS-CoV-2 neutralizing antibody titers.

The neutralizing antibody titers should be at least 1:160 [24]. A titer of 1:80 is admissible if another matched unit is not accessible. In case, neutralizing antibody titers cannot be determined, a retention sample from the donated convalescent plasma must be stored for later determination. However, storing samples for single patient eNIDs is not recommended.

For the registered and licensed blood establishments already authorized for plasma collection for transfusion need not seek an additional license or procure their own IND for collection and preparation of COVID-19 convalescent plasma for the investigational purpose provided they:

1. Follow their SOPs for plasma collection and all applicable regulations, and  
2. Collect plasma from individuals meeting the donor qualifications detailed above. Once prepared, the COVID-19 convalescent plasma may be distributed for investigational use. Blood establishments do not need to seek an alternative pathway or exception under section 21 CFR 640.120(a) to collect the COVID-19 convalescent plasma.

**Labeling**

The labeling requirements recommendations are:

a. The label of COVID-19 convalescent plasma container must mention the statement, “Caution: New Drug—Limited by Federal (or US) law to investigational use.” [21 CFR 312.6(a)]. In addition, the requirements in 21 CFR 606.121 for the container label applies, along with inclusion of a note for the circular of information (on use of plasma).

b. FDA recommends the use of a uniform container label for COVID-19 convalescent plasma. Specifically, the uniform labeling of blood and blood components using ISBT 128 has been recommended.

c. The shelf-life and storage guidelines on the label for COVID-19 convalescent plasma should be the same as for other plasma products. For example, fresh frozen COVID-19 convalescent plasma should be frozen within eight hour after collection, stored at ≤18°C, and labeled with a shelf-life of one year from date of collection [14,22].

**Recordkeeping**

The records for the COVID-19 convalescent plasma unit(s) administered to the COVID-19 patient [21 CFR 312.62] must be maintained by health care provider. These records should include the unique identification number of the plasma units [22].

**AUTHORISATION OF CONVALESCENT PLASMA COLLECTION, TESTING, PROCESSING, STORAGE, AND DISTRIBUTION**

The blood establishments meeting the criteria for donation, collection, processing, and testing are authorized by competent authority to proceed unless the National regulatory authority enforces more stringent requirements or their existing authorization already covers the activities for plasma transfusion, including convalescent plasma [25]. This facilitates the rapid creation of national inventories of COVID-19 convalescent plasma.

Blood establishments that have adopted measures for gathering outcome data to ensure safety and quality can be authorized for convalescent plasma distribution [21].

**Collection, processing, and storage**

Instead of whole blood, plasmapheresis is preferred to improve the yield of convalescent plasma. Apheresis is an automated technology in which whole blood is continuously centrifuged into its components (namely, red blood cells, platelets, and plasma), followed by a selective collection of the desired blood component returning remaining components to the donor. This highly efficient procedure generates around 400–800 ml of plasma from a single apheresis donation. In general, donors donate plasma by plasmapheresis, but if such facilities are not available, whole blood can be collected, followed by plasma separation in the blood establishment [26]. For those repeating donation, an average donation gap of 2 weeks is advised.

Plasma obtained by plasmapheresis should be divided into 2–3 separate units (3 × 200 ml) before freezing. The units are frozen within 24 h of collection and quarantined until reports are obtained from standard blood donor testing for transfusion-transmitted infections. Final products should be appropriately labeled as COVID-19 convalescent plasma/blood and appropriately stored. Pathogen reduction should be done if it is normally followed in the blood establishment and care should be taken not to introduce pathogen. Any serious adverse reactions in the donor should be notified to the competent authority without delay [21,27,28].

**Testing of donated plasma**

In addition to the general quality-control tests and the test for blood-borne diseases, the blood samples need to be tested for:

1. Nucleic acid testing for SARS-CoV-2;
2. 160-fold dilution for the qualitative test of SARS-CoV-2 specific IgG and IgM detection; or 320-fold dilution for the qualitative test of whole antibody detection. If possible, keep aside >3 mL of plasma for the viral neutralization experiments.

While comparing virus neutralization titer and luminescent IgG antibody quantitative detection, it was found that the present SARS-CoV-2 specific IgG antibody detection does not fully demonstrate the actual virus neutralization capability of the plasma. Therefore, the virus neutralization test was suggested as the first choice, or determines the overall antibody level with the 320-fold dilution of the plasma [29]. It is recommended that neutralizing antibody titers should optimally be more than 1:320, but lower thresholds might also be clinically effective. When the measured neutralizing activity in the collected plasma is found to be low, the plasma can be fractionated and used for other clinical applications.

Ideally, a test for the existence of the anti-SARS-CoV-2 antibody should be accomplished through neutralizing antibody testing before using convalescent plasma. In case of emergency, where convalescent plasma is transfused without antibody testing, a sample should be stored and tested later. If an appropriate correlation can be demonstrated between neutralizing activity and ELISA antibody testing, it can replace the neutralizing antibody test. Therefore, it is suggested that additional samples of the donated plasma should be archived for reference studies. Thus 10 × 0.5 mL frozen aliquots from plasma samples can be withdrawn at the time of donation. In the case of repeated donations, plasma should be collected from donors showing higher titers rather than the ones with lower titers, based on the collection capacity [21,27].

**Distribution of COVID-19 convalescent plasma**

Blood establishments can distribute convalescent plasma to a hospital, on the request, when the specific patient:

- Has laboratory-confirmed COVID-19,  
- Has been hospitalized either due to acute illness or risk of acute illness,  
- Has accorded informed consent.

It is advisable to inform the potential recipient(s) about the uncertainty in the efficacy of convalescent plasma therapy in treating COVID-19 to
Avoid promoting unsubstantiated expectations. The recipient may be a part of a clinical trial or monitored use. This helps in making informed decisions regarding treatment by the prospective recipients.

Blood services should provide convalescent plasma with the highest antibody titers available. Furthermore, the dose of transfused plasma should be adjusted based on its neutralizing antibody titer and the volume of plasma of the recipient. Convalescent plasma in an approved randomized or case-controlled clinical trial should be distributed as per the protocol of that trial and, where necessary, in compliance with national legislation [21,30,31]. To ensure safety, quality, and amend improvements in the collection, testing, processing, and storage protocols, the hospitals should furnish defined clinical outcomes to the supplier blood establishment [32]. The information to be included in the outcome data should entail:

1. Gender, co-morbidities, age range (20–29, 30–39, etc.),
2. Transfusion time point (days from the onset of disease)
3. Volume, number, and antibody titer of the transfused plasma unit
4. Clinical treatment given to the patient in parallel (other than supportive care)
5. Clinical symptoms and laboratory parameters according to the progression of disease at the following time points (i) before the transfusion, (ii) more than 5 days after transfusion, and (iii) at discharge (if the patient survives)
6. Length of hospitalization (if the patient survives)
7. Any adverse reactions or events potentially linked to the transfusion.

The outcome data in the above format should be reported to the supplying blood establishments and, through them, to the national database to establish a comprehensive scenario at the national level. The data from controlled clinical trials should be first evaluated according to a pre-defined analytical strategy in the clinical trial protocol and published as early as possible. The minimum outcome data should also be reported to the national database to allow meta-analysis in a larger dataset later on. Severe adverse reactions or events possibly linked to the transfusion should be notified by the hospitals to the supplying blood establishments and after that to the competent authority without delay. This reporting is essential whether the plasma has been transfused in an observational study or a controlled clinical trial [21].

PROCEDURE FOR CONVALESCENT PLASMA THERAPY PHASE

Consecutively critically ill patients admitted to the intensive care unit, or other areas of the hospital should be selected based on the following criteria [33]:

Inclusion criteria

Same as discussed for patient eligibility

Exclusion criteria

1. Negative Reverse transcription-polymerase chain reaction (RT-PCR) of respiratory secretion samples.
2. Reported history of a hypersensitive reaction to blood products or plasma.
3. Clinical situation where in administering 500 ml i.v. volume may be harmful to the patient (e.g., actively decompensated congestive heart failure).
4. Severe multi-organ failure, hemodynamic instability.
5. Other documented uncontrolled infection.
6. Patient is expected to survive for <48 h.
7. Severe DIC (disseminated i.v. coagulation) needing factor replacement, fresh frozen plasma (FFP), and cryoprecipitate.

Informed consent

The treating physician and/or the protocol coordinator will describe the purpose of this intervention and its possible benefits and risks to the patient or donor (or to his/her surrogate decision-maker). They will obtain the following consent forms in and as appropriate [33].

For the collection of convalescent plasma

1. Informed consent for COVID-19 RT-PCR and COVID-19 serologic testing for the donors.
2. Informed consent for donation of convalescent plasma from those with elevated anti-SARS-CoV-2 titers as described below.

For the Convalescent plasma therapy phase

A. Consent for enrollment in the convalescent plasma therapy phase
B. Protocol procedures for the convalescent plasma collection phase
1. Eligible candidates for convalescent plasma donation (as per the inclusion and exclusion criteria above) will be tested for anti-SARS-CoV-2 serology. Subjects who are seropositive will be further screened for SARS-CoV-2 RT-PCR.
2. Subjects with an anti-SARS-CoV-2 titer of either more than or equal to 1:80 and negative RT-PCR confirmation of COVID-19 infection will be selected for qualification for donating plasma according to the standard criteria following the WHO guidelines assessing donor acceptability for donating blood.
3. Individuals fulfilling all the criteria for the plasma donation will be called for donation.

Apheresis may be used to collect plasma (500–600 ml on the basis of weight), as suitable for every donor [34]. The collection will be made by trained personnel of blood bank working as per the standard operating procedures in certified laboratories. The frozen plasma is stored at an appropriate temperature in the blood bank after reported negative for a series of serological tests in accordance with the international guidelines [20,33,35].

Infusion plan

The general dosage of convalescent plasma therapy is ~400 ml for one infusion or ~200 ml per infusion for multiple infusions. The intervention consists of administering 2 units of convalescent plasma. Both the units of plasma (200–250 ml) should be infused over 2 h maintaining a gap of 1 h between the two units. Plasma transfusion will be done as per the standard policies recommended for administering blood products [33,36].

Clinical co-interventions

The clinical team exercises independent control of patient management other than convalescent plasma therapy and will not be influenced by the intervention team. Co-interventions such as administration of hydroxychloroquine, Kaletra or darunavir/ritonavir, tocilizumab, corticosteroids, ribavirin, and interferon will be recorded on the patient report sheets. The frequency of clinical and laboratory assessment follow-up is done at baseline, followed by day 1, 3, 5, 7, 14, and after 28 days after administration of convalescent plasma [33].

Outcome measures

These may be classified as clinical and laboratory outcomes, as mentioned in Table 3.

Safety measures

Under conditions of an acute transfusion reaction, the transfusion should be stopped immediately and must be reported immediately to the blood bank, the principal investigator and the study management committee. All the serious adverse events related to the convalescent plasma should be recorded [6,33,38].

CLINICAL USE OF THE CONVALESCENT PLASMA

Indication

1. Severe or critically ill COVID-19 patients tested positive in respiratory tract test;
2. The COVID-19 patients who are not severe or critically ill but in a state of immunity suppression; or have low CT (cycle threshold) values in the virus nucleic acid testing but with a rapid disease progression in the lungs [36].

9
Laboratory outcomes

- Virological clearance at day 7, 14, 21
- CT values for SARS-CoV-2 PCR positivity (RT-PCR) at days 0, 7, 21 when available
- Determining anti-SARS-CoV2 titers at day 0 and thereafter

Contraindication
1. Allergy history of plasma, sodium citrate, and methylene blue;
2. For patients with a history of autoimmunity system diseases or selective IgA deficiency, the application of convalescent plasma should be evaluated cautiously by clinicians [36,39-42].

Convalescent plasma trial for COVID-19 in India
Central Drugs Standard Control Organization (CDSCO) of India has entrusted permission to the Indian Council of Medical Research (ICMR) for the clinical trial of convalescent plasma for COVID-19 therapeutics. A list of institutes interested in conducting clinical trials has been submitted by the ICMR. The trial shall be conducted as an open-label, randomized, controlled Phase II study to assess the safety and efficacy of convalescent plasma in patients with moderate COVID-19 disease. Encouraging results were obtained in a small case involving five critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). Infusion of convalescent plasma containing neutralizing antibodies led to substantial clinical improvement in all patients without any deaths [43]. In another group of four patients that included one pregnant woman, convalescent plasma transfusion led to complete recovery eventually [44,45].

In the light of public interest, the ICMR's proposal for conducting a trial was reviewed by the Subject Expert Committee in its meeting held on 13 April under the accelerated approval process owing to the prevailing pandemic. Further, no objection was raised by the CDSCO for the conduct of clinical trial subject to few amendments in the trial protocol and various conditions specified in the Drugs and Clinical Trial Rules, 2019 [46].

The Union Health ministry released clinical management protocols for COVID-19 on June 27, 2020. They allowed the use of convalescent plasma (off-label) to treat COVID-19 patients in a moderate stage of the illness under “investigational therapies,” as mentioned in the CDSCO notice, “Information on Convalescent Plasma in COVID-19.” As per the CDSCO notice, convalescent plasma may be used in moderately infected patients and those that are not improving (the oxygen requirement is progressively increasing) despite the steroidal therapy. Further, the recipient should be kept under strict observation for several hours after transfusion to monitor any adverse events. The application of convalescent plasma should be prevented in patients with immunoglobulin allergy of immunoglobulin A deficiency [47].

**CLINICAL TRIALS TO ASSESS THE EFFICACY AND SAFETY OF HUMAN ANTI-SARS-COV-2 PLASMA**

The use of convalescent plasma has documented successful historical records, as many controlled trials have been conducted to assess its efficacy as an emergency application during epidemics. In the current situation, at least five clinical trials should be carried out to evaluate the effectiveness of human anti-SARS-CoV-2 plasma for the prevention and treatment of COVID-19.

The first trial involves the use of human anti-SARS-CoV-2 plasma as post-exposure prophylaxis: a randomized, blinded Phase II trial for comparing the safety, and efficacy of human anti-SARS-CoV-2 plasma against control (SARS-CoV-2 non-immune plasma) in adults (age more than 18 years) who have had close contact exposure to COVID-19, but are asymptomatic. Close contact exposure refers to be in the periphery of within approximately 2 m (6 ft) of a COVID-19 patient for a substantial duration without personal protective equipment. Close contact also refers to living with, visiting, caring for, or sharing a healthcare waiting area or room with a COVID-19 infected individual or direct contact with infectious secretions of a COVID-19 patient without PPE.

If the first trial is successful, safe, and effective, post-exposure prophylaxis will offer therapeutic intervention for vulnerable populations, namely immunocompromised patients, health care workers, nursing home residents, and individuals with respiratory, following exposure. This would confer direct clinical benefit for those at high risk and would impact more significant social benefits to the frontline workers in the pandemic.

The second trial will assess human anti-SARS-CoV-2 plasma for offering initial help to mildly infected patients. The target population can be symptomatic individuals with confirmed SARS-CoV-2. The clinical endpoints would be the prevention of hypoxemia in room air, suppression of symptoms, or progression to severe disease, reflecting a decline in complications not requiring hospitalization.

In the third trial, moderately ill patients will be investigated to assess the effect of human anti-SARS-CoV-2 plasma on them. The target population will be hospitalized COVID-19 patients showing clinical symptoms but not requiring ICU admission (specifically mechanical ventilation). Aversion to critical illness could avoid overburdening of essential resources of care.

A fourth trial could assess whether human anti-SARS-CoV-2 plasma can act as a rescue intervention in COVID-19 patients requiring mechanical ventilation. This target group is significant as it is a group, for which the data are most challenging to interpret due to the confounding variables, including other putative therapies for COVID-19.

Finally, a fifth trial evaluates the safety and pharmacokinetics of convalescent plasma in high-risk pediatric patients. Although comparatively rare, severe illness, and even deaths due to COVID-19 have been described in children [48], requiring the need to address the risk to children.

Complementing these four trials, studies are being designed to collect and mine data from emergency use of convalescent plasma or expanded access treatment.

**REPORTED CLINICAL TRIALS**

Institute of Liver and Biliary Sciences, India, has undertaken clinical trials to determine the effectiveness of convalescent plasma therapy in severely infected COVID-19 patients. A randomized controlled trial was planned to evaluate the efficacy of this therapy in COVID-19 patients. Five hundred milliliters of convalescent plasma were collected from the COVID-19 recovered patient after 14 days of clinical and radiological recovery with two consecutive COVID-19 negative tests by PCR. Further, the samples from the collected plasma for COVID-19 specific antibodies and their titer were tested. This plasma was frozen and sent to the treating center (Maulana Azad Medical College). 200–600 ml of convalescent plasma was transfused to patients fulfilling the eligibility criteria and was randomized.
to the convalescent plasma group. This was accomplished in critically ill patients. The data were collected for the clinical benefit and monitored the adverse events related to the transfusion [17].

Globally, various clinical trials have been recruited or are yet to be recruited to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients. A few of them are listed in Table 4.

| Study title                                                                 | Intervention                                                                 | Status        | Location                                                                 |
|----------------------------------------------------------------------------|------------------------------------------------------------------------------|---------------|--------------------------------------------------------------------------|
| Convalescent plasma trial in COVID-19 patients [51]                         | Other: Plasma therapy using convalescent plasma with the antibody against SARS-CoV-2 Other: Routine care for COVID-19 patients | Completed     | Royal College of Surgeons, Ireland                                       |
| Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients [52] | Other: Blood and derivatives. Drug: Standard of Care                          | Recruiting    | Hospital Clínico Universitario Lozano Blesa Zaragoza, Aragón, Spain       |
|                                                                            |                                                                               |               | Hospital Universitario Severo Ochoa Leganés, Madrid, Spain              |
|                                                                            |                                                                               |               | Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain     |
|                                                                            |                                                                               |               | Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain     |
|                                                                            |                                                                               |               | Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain     |
| Efficacy of convalescent plasma therapy in severely sick COVID-19 patients [17] | Drug: Convalescent Plasma Transfusion Other: Supportive Care Drug: Random Donor Plasma Biological: Convalescent plasma | Completed     | Maulana Azad medical College New Delhi, Delhi, India                     |
|                                                                            |                                                                               |               | Institute of Liver and Biliary Sciences New Delhi, Delhi, India          |
|                                                                            |                                                                               |               | Erasmus Medical Center Rotterdam, Zuid-Holland, Netherlands             |
|                                                                            |                                                                               |               | NoordWest ziekenhuis groep Alkmaar, Netherlands Onze Lieve Vrouwen Gasthuis Amsterdam, Netherlands |
| Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 [54]      | Biological: Convalescent Plasma Other: Standard of Care                       | Recruiting    | Maulana Azad Medical College, New Delhi, India                           |
|                                                                            |                                                                               |               | Institute of Liver & Biliary Sciences, New Delhi, India                 |
|                                                                            |                                                                               |               | Rajiv Gandhi Super Specialty Hospital New Delhi, India                  |
|                                                                            |                                                                               |               | Gatot Soebroto central army presidential hospital Jakarta Pusat, Indonesia |
|                                                                            |                                                                               |               | Alkarkh Health directorate Baghdad, Iraq                                |
| Convalescent Plasma Therapy in Patients With COVID-19 [55]                 | Biological: Convalescent plasma                                               | Completed     | Bangabandhu Sheikh Mujib Medical University Dhaka, Bangladesh            |
|                                                                            |                                                                               |               | Biltspendezentrum SRK beider Basel, University Hospital Basel, Switzerland |
| Convalescent Plasma Therapy on Critically-Ill Novel Coronavirus (COVID-19) Patients [56] | Biological: Convalescent plasma Drug: Hydroxychloroquine with Azithromycin | Completed     | Danderyd Hospital, Danderyd, Stockholm, Sweden                           |
| Convalescent Plasma Therapy in Severe COVID-19 Infection [57] Amotosalen-UV A pathogen-inactivated convalescent plasma in addition to best supportive care and antiviral therapy on clinical deterioration in adults presenting with moderate to severe COVID-19 [58] | Biological: Convalescent plasma Other: Convalescent plasma administration to SARS-CoV-2 infected patients | Recruiting     | Columbia University Irving Medical Center/NYP New York, New York, United States |
| Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study [59] | Biological: SARS-CoV-2 convalescent plasma                                   | Recruiting     | Brigham and Women’s Hospital, Boston, Massachusetts, United States      |
| Convalescent Plasma Treatment in COVID-19 [60]                             | Biological: convalescent plasma (CP) Other: Drugs and supportive care        | Recruiting     | General Hospital, University of Sao Paulo, Brazil                        |
| Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma therapy [61] | Biological: High-Titer COVID-19 Convalescent Plasma (HP-CCP)                  | Recruiting     | Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States |
| Plasma therapy of COVID-19 in critically ill patients [62]                 | Biological: Standard Plasma                                                    | Recruiting     | Cairo University Hospital Cairo, Egypt                                   |
| Treatment of patients with COVID-19 with convalescent plasma [63]          | Biological: convalescent plasma                                              | Recruiting     |                                |
CONCLUSION

The risks due to COVID-19 infection are vast. Convalescent plasma obtained from recovered COVID-19 patients has been proposed to be a potentially effective and safe therapy for treatment and post-exposure prophylaxis alike. Several evidence of benefit with prior use for viral infections offers strong precedent for such an approach. The availability of limited data from precisely controlled clinical trials of convalescent plasma necessitates evaluating its use objectively for a range of indications and patient populations. However, performing well-controlled clinical trials is critically important to confirm efficacy, so rational evidence-based decision-making can be made.

AUTHORS' CONTRIBUTIONS

Amit Porwal: Writing-original draft preparation. Kamla Pathak: Writing-reviewing, and Editing. Devender Pathak: Validation. Ramakant Yadav: Conceptualization and Review

CONFLICTS OF INTEREST

There are no conflicts of interest.

FUNDING

As this is a review article, no funding was provided for this study.

REFERENCES

1. Liang T. Handbook of COVID-19 Prevention and Treatment. Zhejiang: University School of Medicine; 2020. p. 35-6. Available from: https://www.issuu.com/iknowcorp/docs/handbook_of_covid-19_prevention__english_version.
2. World Health Organization. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment During Outbreaks: Interim Guidance for National Health Authorities and Blood Transfusion Services; 2014. Available from: https://www.euro.who.int/__data/assets/pdf_file/0011/268787/Use-of-Convalescent-Whole-Blood-Or-Plasma-Collected-from-Patients-Recovered-from-Ebola-Virus-Disease-for-Transfusion,-as-an-Empirical-Treatment-during-Outbreaks-Eng.pdf.
3. Griensven JV, Edwards T, de Lamballerie X. Ebola-Tx consortium. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016;374:33-42.
4. Marano G, Vaglio S, Papella S, Facco G, Catalano L, Liambrouro GM, et al. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus 2016;14:152-7.
5. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000;13:602-14.
6. Stieltjes B, Verheugen M, van der Wal C, Boomsma FE. An augmented passive immune therapy to treat fulminant bacterial infections. Rec Pat Immune Ther 2010;5:157-67.
7. Marano G, Vaglio S, Papella S, Facco G, Catalano L, Liambrouro GM, et al. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus 2016;14:152-7.
8. Rajam G, Sampson J, Carlome GM, Ades EW. An augmented passive immune therapy to treat fulminant bacterial infections. Rec Pat Immune Ther 2010;5:157-67.
9. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000;13:602-14.
10. Yadav R, Pathak K, Pathak D, Kumar R. Chemoprophylactic. Ayurvedic, homeopathic and unani approaches for COVID-19 prophylaxis. Pharm Biomed Res 2020;6:341.
11. Robbiani DF, Guebler C, Muecksch F, Lorenzi JC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020;584:437-59.
12. Marano G, Vaglio S, Papella S, Facco G, Catalano L, Liambrouro GM, et al. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus 2016;14:152-7.
13. Agarwal A, Mulkherjee A, Kumar G, Chatterjee P, Bhattacharjee S, Bhattacharjee T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:m3939.
14. COVID-19: What is Convalescent Plasma? Health, The Sciences. 2020. Available from: https://www.science.thewire.in/the-sciences/covid-19-what-is-convalescent-plasma.
15. Arafah Y, Hajee AH, Luke T, Raviprakash K, Balkhy H, Johani A, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016;22:1554-61.
16. Cheng Y, Wong R, Soo YO. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24:44-6.
17. Devanesanathy N, Ye Z, Loeb M, Fang F, Najafabadi BT, Xiao Y, et al.
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: A systematic review and meta analysis. CMAJ 2020;192:E745-55.

14. US Food and Drug Administration: Investigational COVID-19 Convalescent Plasma (Guidance for Industry). FDA 2020. Available from: https://www.fda.gov/vaccines-biotherapies/investigational-new-drug-ind-or-device-exemption-ide-process-chef/recommendations-investigational-covid-19-convalescent-plasma.

15. Joyner M, Wehby RS, Fairweather D, Sonfeld J, Bruno J, Klassen S, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest 2020;130:4701-7.

16. Joyner M. Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19. 2020. Available from: https://www.usevpdplasma.org/pdf/Covid-19%20ConvPlasm%20EAP.pdf.

17. Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients. Institute of Liver and Biliary Sciences, India 2020. Available from: https://www.mohfw.gov.in/pdf/CLINICAL_MANAGEMENT_PROTOCOL_COVID-19.pdf. [Last accessed on 2020 Aug 25].

18. Guide on the Compassionate Use of Convalescent Plasma Therapy for Covid-19. UP-Philippine General Hospital Technical Working Group; 2020. Available from: http://www.isbtweb.org/fileadmin/user_upload/Deenome_Thaddeus_V_Gaurian_Philippines.pdf.

19. Guidelines on Clinical Management of COVID-19. Ministry of Health and Family Welfare, Government of India. 2020. Available from: http://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf.

20. Smid WM, Burnout T, Epstein J, Kamer H, Sibinga CS, Somuah D, et al. Post-transfusion anaphylactic shock in the Preparation and Transfusion of COVID-19 Convalescent Plasma in low- and Middle-Income Countries; 2020. Available from: http://www.isbtweb.org/fileadmin/user_upload/FINAL_Points_to_consider_in_the_preparation_of_COVID_convalescent_plasma_in_LMIC.pdf.

21. An EU Project to Collect COVID-19 Convalescent Plasma Collection and Transfusion: Guidance on Collection, Testing, Processing, Storage, Distribution and Monitored Use. European Commission, Directorate-general for Health and Food Safety; 2020. Available from: https://www.ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/weaknesses_plasmapheresis_en.pdf.

22. Recommendations for Investigational COVID-19 Convalescent Plasma. USFDA; 2020. Available from: https://www.fda.gov/vaccines-biotherapies/investigational-new-drug-ind-or-device-exemption-ide-process-chef/recommendations-investigational-covid-19-convalescent-plasma.

23. Hassan MO, Osman AA, Elbasit HE, Hassan HE, Rufai H, Satti MM, et al. Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan. Transfusion Apheresis Sci 2020;59:1-5.

24. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Efficiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020;117:9490-1.

25. Guidelines on Good Manufacturing Practices for Blood Establishments, TRS 961, 2011. Available from: https://www.who.int/bloodproducts/publications/gmp_bloodestablishments.pdf.

26. Epstein J, Burnout T, Points to Consider in the Preparation and Transfusion of COVID-19 Convalescent Plasma. Working Party of Global Blood Safety, International Society of Blood Transfusion; 2020. Available from: https://www.isbtweb.org/fileadmin/user_upload/Points_to_consider_in_the_preparation_of_COVID_convalescent_plasma - 200331.ISBT_WP_GBS_Final.pdf.

27. Bloch EM, Bailey JA, Tobian AA. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757-65.

28. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398-400.

29. Li L, Yang R, Wang J, Lv Q, Ren M, Zhao L, et al. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. Transfusion 2020;60:1773-7.

30. Pan American Health Organization (PAHO), Regulatory Considerations on Authorization of the Use of Convalescent Plasma (PC) to Address the COVID-19 Emergency; 2020. Available from: https://www.iris.paho.org/handle/10665/250326.

31. World Health Organization. Guidelines on good manufacturing practices for blood establishments. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report. Geneva: World Health Organization; 2011. Available from: http://www.who.int/bloodproducts/publications/GMP_Bloodestablishments.pdf.

32. Elback JD, Joyner M. Convalescent plasma to treat COVID-19: Possibilities and challenges. JAMA 2020;323:1561-2.

33. Protocol for the Use of Convalescent Plasma for the Treatment of COVID-19 Infected Patients; 2020. Available from: http://www.isbtweb.org/fileadmin/user_upload/Qatar.pdf.

34. Huangd S. Use of Convalescent Plasma in the Treatment of Patients Infected with Covid-19 Virus Infection (SARS-cov-2); 2020. Available from: https://www.isbtweb.org/fileadmin/user_upload/Convalescence_Plasma_Protocol_for_COVID19_March_2020.pdf.

35. World Health Organization. Blood Donor Selection: Guidelines on Assessing Donor Suitability for Blood Donation. Geneva: World Health Organization; 2020. Available from: https://www.apps.who.int/iris/handle/10665/76724.2012.

36. Accorsi P, Berti P, Angelis VD, Silvestro GD, Mascarelli L, Ostuni A. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Blood Transfus 2020;18:163-6.

37. WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20:e192-7.

38. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2003;361:1555-9.

39. CDSCO. Information on Convalescent Plasma in COVID-19; 2020. Available from: https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/ISBNHV/convalescentplasmainCovid19.pdf.

40. CLINICAL MANAGEMENT PROTOCOL: COVID-19; 2020. Available from: https://www.mohfw.gov.in/pdf/CLINICAL_MANAGEMENT_PROTOCOL_COVID-19.pdf.

41. Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reaction: a case series. Transfus Med 2020;30:88-90.

42. Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: State of the art. Clin Microbiol Rev 2020;33:e00072-20.

43. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-9.

44. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020;156:e1-13.

45. CDSCO. A Phase II, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease; 2020. Available from: https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/CDSCO%20Convalescent%20Plasma%20COVID19Draft.pdf.

46. India’s CDSCO Permits Convalescent Plasma Trial for Covid-19; 2020. Available from: https://www.clinicaltrialsarena.com/news/india-convalescent-plasma.

47. Convalescent Plasma for COVID-19 Patients Not Responding to Steroids: CDSCO; 2020. Available from: https://www.outlookindia.com/news/scroll/convalescent-plasma-for-covid-19-patients-not-responding-to-steroids-cdsco/1883559.

48. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 21434 patients with 2019 coronavirus disease in China. Pediatrics 2020;145:e202000702.

49. Pathak K, Pathak D, Yadav R, Kumar R. COVID-19: An update on therapeutic and clinical trials. Int J Pharm Sci Drug Res 2020;12:1-9.

50. U.S. National Library of Medicine. 2020. Available from: https://www.clinicaltrials.gov/ct2/results?cond=convalescent+plasma+therapy+dosage+for+covid+19&term=&cntry=&state=&city=&dist.

51. CDSCO. Information on Convalescent Plasma in COVID-19; 2020. Available from: https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/CDSCO%20Convalescent%20Plasma%20COVID19Draft.pdf.

52. Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients. Spain: Cristina Avendaño Solá, Puerta de Hierro University Hospital; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04356531.

53. Convalescent Plasma Therapy for COVID-19 Patients. India: Institute of Liver and Biliary Sciences; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04425915.

54. Convalescent Plasma Therapy in Patients with COVID-19. Jakarta Pusat, Indonesia: Gatot Soebroto Central Army Presidential Hospital; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04407208.

55. Convalescent Plasma Therapy on Critically-ill Novel Coronavirus
57. Convalescent Plasma Therapy in Severe COVID-19 Infection. Bangladesh: Bangabandhu Sheikh Mujib Medical University Dhaka; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04403477.

58. Amotosalen-UV A Pathogen-inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting with Moderate to Severe COVID-19. Basel, Switzerland: Blutspendezentrum SRK Beider Basel, University Hospital; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04389944.

59. Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study. Sweden: Danderyd Hospital, Danderyd, Stockholm; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04384497.

60. Convalescent Plasma Treatment in COVID-19. Pakistan: Aga Khan University Hospital, Karachi, Sindh; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04476888.

61. Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma Therapy. Massachusetts, United States: Brigham and Women’s Hospital, Boston; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04361253.

62. Plasma Therapy of COVID-19 in Critically Ill Patients. New York, United States: Columbia University Irving Medical Center; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04359810.

63. Treatment of Patients with COVID-19 with Convalescent Plasma. Brazil: General Hospital, University of Sao Paulo; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04415086.

64. Convalescent Plasma for the Treatment of COVID-19. Philadelphia, PA, Pennsylvania, United States: Thomas Jefferson University Hospital; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04389710.

65. Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection. Egypt: Cairo University Hospital Cairo; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04438694.

66. Convalescent Plasma for the Treatment of Patients with COVID-19. United States: Children’s Hospital Colorado, Aurora, Colorado; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04372368.

67. Convalescent Plasma as Treatment for Hospitalized Subjects with COVID-19 Infection. New Jersey, United States: Hackensack University Medical Center; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04343755.

68. Convalescent Plasma for the Treatment of Patients with Severe COVID-19 Infection. Attiki, Greece: Evangelismos General Hospital, Athens; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04408209.

69. Convalescent Plasma as a Possible Treatment for COVID-19. Chicago, Illinois, United States: University of Illinois at Chicago; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04442191.

70. Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19. Albuquerque, New Mexico, United States: University of New Mexico Health Sciences Center; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04434131.

71. Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19. Albert Lea, Minnesota, United States: Mayo Clinic Health System in Albert Lea; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04338360.

72. Experimental Expanded Access Treatment with Convalescent Plasma for the Treatment of Patients with COVID-19. Massachusetts, United States: UMass Medical School Worcester; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04445207.

73. Safety in Convalescent Plasma Transfusion to COVID-19. Nuevo Leon, Mexico: Hospital San José, Monterrey; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04333155.

74. Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia. Aguascalientes, Mexico: Centenario Hospital Miguel Hidalgo; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04381858.